AKT1 and neoplasm: Activation of the AKT pathway can occur through homozygous loss of the PTEN tumour suppressor gene, but there is no definite prognostic significance for PTEN loss in mRCC [136,137], and there does not appear to be a correlation between tumour PTEN expression and benefit from temsirolimus [138].